I. Bitter, Hungary

Semmelweis University Dept. Psychiatry and Psychotherapy
Prof. Istvan Bitter graduated from the Semmelweis University, Budapest Hungary. His board exams include: neurology, psychiatry, psychotherapy and clinical pharmacology. Past president of the Hungarian Psychiatric Association. Active member of the Schizophrenia Network of ECNP, board member of the Hungarian Brain Research Program, chair of the Section of Psychopharmacology of the European Psychiatric Association. Former visiting physician (1 year) in Germany, visiting professor of the New York University and research scientist of the N.S. Kline Institote for Psychiatric Research , Orangeburg, NY (3 years) and also industry experiment (head of the CNS clinical research unit of a regional hub of a large multinational pharmaceutical company for 3 years). Chair of the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest between 2004 and 2014. Current chair of the national (central) Clinical Pharmacological Ethics Committee. He published 300+ papers, book chapters and books with 11551 citations, H index=43 (Google Scholar, 25.02.2021), including “Managing Negative Symptoms of Schizophrenia” (Oxford University Press, 2020).

Moderator Of 2 Sessions

Date
Mon, 12.04.2021
Session Time
17:30 - 19:00
Room
Channel 4
Session Description
The Live Q&A of this session will take place in the Live Sessions auditorium. Please refer to the interactive programme for the exact time and channel.

In March 2020, the World Health Organization (WHO) declared the COVID-19 virus (known as Coronavirus) a global pandemic leading to almost ubiquitous public health restrictive measures. Both the COVID-19 pandemic and the applied restrictive measures can have marked acute and long-term detrimental effects on physical and mental health-related quality of life and every-day functioning of the general population, but also in particular in specific population groups. Thus, apart from the actual COVID-19-infection-related health complications, indirect physical and mental health complications might represent the most crucial and still unpredictable public-health-related aspect of the pandemic and call for a careful assessment at a global level. The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is the currently largest-scale global study on the overall health impact of the COVID-19 pandemic and applied restrictive measures in the general population, representing a unique collaboration between over 200 researchers, across over 40 countries and six continents. The elaborated design of the COH-FIT study can identify non-modifiable and modifiable multisystem risk and resilience factors in such an unprecedented time. Results will inform and facilitate acute and long-term interventions and preventive responses at a policy, health care and individual level, to better adapt to challenges inflicted by the ongoing pandemic and possible future global crises. This symposium presents the project background and methodology and offers an overview of the most important results of the global COH-FIT sample of over 80,000 in adult, adolescent and children participants.

Session Icon
Pre-Recorded with Live Q&A
Clinical/Therapeutic
Date
Sun, 11.04.2021
Session Time
10:00 - 11:30
Room
Channel 3
Session Description
Proposed by the EPA section on Psychopharmacology -Psychopharmacology during Infections, including COVID-19 Infectious diseases are more frequent among people with psychiatric disorders as compared to the general population and they significantly contribute to the higher mortality rates observed in psychiatric disorders, e.g. schizophrenia, depression, bipolar disorders. Psychiatric residency training and continuing medical education for psychiatrists provide very limited or no information about the management of psychiatric patients with infectious diseases. The COVID-19 pandemic confronted the health care systems with enormous challenges, including the treatment of psychiatric patients suffering from coronavirus infection. The main objectives of this symposium are: 1. to provide data about the importance of infections for patients with psychiatric disorders; 2. to provide state of the art information about the management of patients with comorbid psychiatric disorders and infectious diseases; 3. to help integrating the lessons learned from COVID-19 pandemic into psychiatric practice. The following specific topics will be addressed: 1. The prevalence of comorbidity and mortality associated with infectious diseases in patients with psychiatric disorders (presenter: Istvan Bitter, Hungary); 2. The challenges of psychopharmacological treatment during the COVID-19 pandemic in Lombardy* (presenter: Antonio Vita, Italy); 3. The interactions between Covid-19 drugs and psychotropic agents (presenter: Christoph Hiemke, Germany); 4. The pharmacotherapy of infections in patients with mental disorders receiving psychotropic drugs: focus on good practices (presenter: Matej Stuhec, Slovenia). * Lombardy is one of the regions in the world hardest hit by the COVID-19 pandemic.
Session Icon
Live, Section

Presenter Of 5 Presentations

Symposium: The Collaborative Outcomes Study on Health and Functioning During Infection Times (COH-FIT): Results in Adults and Youth From Over 130 Countries (ID 283) No Topic Needed
Workshop: Unmet Needs in Modern Psychiatric Practice: a Collaborative Workshop between the Committee on Education and EPA Scientific Sections (ID 298) No Topic Needed
LIVE - Symposium: Psychopharmacology During Infections, Including COVID-19 (ID 302) No Topic Needed

Live Q&A

Session Icon
Live, Section
Date
Sun, 11.04.2021
Session Time
10:00 - 11:30
Room
Channel 3
Lecture Time
11:08 - 11:28
LIVE - Symposium: Psychopharmacology During Infections, Including COVID-19 (ID 302) No Topic Needed

S0021 - The Prevalence of Comorbidity and Mortality Associated with Infectious Diseases in Patients with Psychiatric Disorders

Session Icon
Live, Section
Date
Sun, 11.04.2021
Session Time
10:00 - 11:30
Room
Channel 3
Lecture Time
10:00 - 10:17
Presenter
Workshop: Unmet Needs in Modern Psychiatric Practice: a Collaborative Workshop between the Committee on Education and EPA Scientific Sections (ID 298) No Topic Needed

W0076 - Training in Psychopharmacology in the Modern Psychiatry

Session Icon
Pre-Recorded with Live Q&A
Date
Tue, 13.04.2021
Session Time
15:30 - 17:00
Room
Channel 5
Lecture Time
15:41 - 15:52
Presenter